In a larger patient cohort, the same authors subsequently supported the epidemiological hypothesis that anti-NPM1 immune responses could contain AML development and contribute to a better outcome in NPM1-mutated AML patients who carry favorable HLA class I types, such as A*02, B*07, B*40 and C*07:01 [16]. The gene discussed is NPM1; the disease is acute myeloid leukemia.